Ernexa Therapeutics (ERNAW) Change in Accured Expenses (2010 - 2026)
Ernexa Therapeutics (ERNAW) reported Change in Accured Expenses of $759000.0 for Q1 2026, up 874.49% on a YoY basis from $77886.9 in Q1 2025, and up 326.4% quarter-over-quarter from $178000.0 in Q4 2025.
Ernexa Therapeutics (ERNAW) Change in Accured Expenses (2010 - 2026) Analysis & Trends
Ernexa Therapeutics has reported Change in Accured Expenses for 17 years, with the latest figure at $759000.0 in Q1 2026.
- For the quarter ending Q1 2026, Change in Accured Expenses rose 874.49% year-over-year to $759000.0; the trailing twelve-month figure through Mar 2026 stood at $872000.0 (up 263.91% YoY), and the FY2025 full-year result was $15000.0, down 44.44% from the prior year.
- Change in Accured Expenses for Q1 2026 stood at $759000.0, up from $178000.0 in the prior quarter.
- The five-year high for Change in Accured Expenses was $2.5 million in Q2 2022, with the low at -$1.8 million in Q1 2023.
- Historically, Change in Accured Expenses has averaged $34235.3 across 5 years, with a median of -$86000.0 in 2024.
- Annual changes were most pronounced in 2024 — Change in Accured Expenses tumbled 1620.0% — and 2026, when it jumped 874.49%.
- Ernexa Therapeutics' Change in Accured Expenses stood at -$1.2 million in 2022, then jumped by 99.59% to -$5000.0 in 2023, then plunged by 1620.0% to -$86000.0 in 2024, then jumped by 306.98% to $178000.0 in 2025, then jumped by 326.4% to $759000.0 in 2026.
- The last three Change in Accured Expenses figures came in at $759000.0 (Q1 2026), $178000.0 (Q4 2025), and -$290000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 931,000.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 644,700.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 70.50 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Ernexa Therapeutics | - | - | - | 759,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 759,000.00 |
| Mar 31, 2026 | 759,000.00 |
| Dec 31, 2025 | 178,000.00 |
| Dec 31, 2025 | 178,000.00 |
| Sep 30, 2025 | -290,000.00 |
| Sep 30, 2025 | -290,000.00 |
| Jun 30, 2025 | 225,000.00 |
| Jun 30, 2025 | 225,000.00 |
| Mar 31, 2025 | -98,000.00 |
| Mar 31, 2025 | -98,000.00 |
| Dec 31, 2024 | -86,000.00 |
| Dec 31, 2024 | -86,000.00 |
| Sep 30, 2024 | -112,000.00 |
| Sep 30, 2024 | -112,000.00 |
| Jun 30, 2024 | -236,000.00 |
| Jun 30, 2024 | -236,000.00 |
| Mar 31, 2024 | 461,000.00 |
| Mar 31, 2024 | 461,000.00 |
| Dec 31, 2023 | -5,000.00 |
| Dec 31, 2023 | -5,000.00 |